Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

34.64
+0.41441.21%
Volume:3K
Turnover:89.34K
Market Cap:44.17M
PE:- -
High:34.64
Open:34.48
Low:34.41
Close:34.23
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.76
T/O Rate:0.20%
Dividend:0.08
Dividend Rate:0.22%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

TIPRANKS
·
Aug 27

Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

TIPRANKS
·
Aug 26

Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

TradingKey
·
Aug 26

Eli Lilly Study Shows Lower Healthcare Costs With Zepbound in Older Adults

MT Newswires Live
·
Aug 26

Zepbound Linked to Lower Healthcare Costs in Adults over Age 55 with Obesity According to a Real-World Study

THOMSON REUTERS
·
Aug 26

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Simply Wall St.
·
Aug 26

Sweden's BioArctic Q2 Revenue Falls Despite Higher Leqembi Royalties

Reuters
·
Aug 26

AlzeCure Swings to Q2 FY26 Profit of SEK 80.18 Million; Net Sales Rise to SEK 97.33 Million

Reuters
·
Aug 26

Eli Lilly (LLY) Stock Trades Below Fair Value On Cash Flow

Simply Wall St.
·
Aug 26

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 26

Moderna Inc. Stock Rallies 14.4%, Outperforms Peers

Dow Jones
·
Aug 26

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Simply Wall St.
·
Aug 26

Eli Lilly & Co. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Aug 26

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026

Reuters
·
Aug 26

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026

THOMSON REUTERS
·
Aug 26

Eli Lilly Stock (LLY) Rattled as Companies Decline to Cover Weight-Loss Drug Costs

TIPRANKS
·
Aug 26

More US Employers to Drop Weight-Loss Drugs in 2027, as Healthcare Costs Increase

Reuters
·
Aug 26

Lilly’s LY4395089 Interaction Study Marks Quiet but Important Early-Stage Progress

TIPRANKS
·
Aug 26

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

TIPRANKS
·
Aug 25